Volume 14, Number 1—January 2008
Research
Short- and Long-term Effects of Bacterial Gastrointestinal Infections
Table 4
Complications associated with gastroenteritis, 1 year postinfection, among 101,855 patients with bacterial gastrointestinal infection, Sweden, 1997−2004*
Disease | Infecting organism | Obs | Exp | SIR | 95% CI |
---|---|---|---|---|---|
Digestive system | |||||
Crohn’s disease | Campylobacter spp. | 27 | 17.1 | 1.6 | 1.0–2.3 |
Salmonella spp. | 14 | 10.3 | 1.4 | 0.8–2.3 | |
Shigella spp. | 1 | 1.1 | 0.9 | 0.02–5.2 | |
Yersinia spp. | 2 | 1.1 | 1.8 | 0.2–6.4 | |
Ulcerative colitis | Campylobacter spp. | 42 | 14.8 | 2.8 | 2.0–3.8 |
EHEC | 1 | 0.1 | 6.8 | 0.2–37.7 | |
Salmonella spp. | 29 | 9 | 3.2 | 2.2–4.6 | |
Yersinia spp. | 3 | 1 | 2.9 | 0.6–8.5 | |
Other specified/unspecified noninfective gastroenteritis and colitis | Campylobacter spp. | 37 | 14.9 | 2.5 | 1.8–3.4 |
Salmonella spp. | 30 | 9.2 | 3.3 | 2.2–4.6 | |
Yersinia spp. | 10 | 1.3 | 7.6 | 3.7–14.0 | |
Irritable bowel syndrome | Campylobacter spp. | 15 | 5 | 3.0 | 1.7–5.0 |
Salmonella spp. | 5 | 3 | 1.7 | 0.5–3.9 | |
Yersinia spp. | 3 | 0.4 | 7.8 | 1.6–22.9 | |
Intestinal malabsorption | Salmonella spp. | 1 | 0.6 | 1.7 | 0.04–9.3 |
Yersinia spp. |
1 |
0.1 |
7.9 |
0.2–43.7 |
|
Musculoskeletal system | |||||
Postdysenteric arthropathy, Reiter disease, other reactive arthropathies | Campylobacter spp. | 15 | 2.4 | 6.3 | 3.5–10.4 |
Salmonella spp. | 27 | 1.5 | 18.2 | 12.0–26.5 | |
Shigella spp. | 2 | 0.1 | 13.4 | 1.6–48.4 | |
Yersinia spp. | 9 | 0.2 | 47.0 | 21.5–89.2 | |
Rheumatoid arthritis | Campylobacter spp. | 22 | 22.5 | 1.0 | 0.6–1.5 |
EHEC | 1 | 0.2 | 5.8 | 0.2–32.1 | |
Salmonella spp. | 9 | 14.7 | 0.6 | 0.3–1.2 | |
Shigella spp. | 1 | 1.2 | 0.8 | 0.02–4.7 | |
Yersinia spp. | 3 | 1.5 | 2.0 | 0.4–5.7 | |
Other arthritis | Campylobacter spp. | 8 | 3.8 | 2.1 | 0.9–4.2 |
Salmonella spp. | 4 | 2.5 | 1.6 | 0.4–4.1 | |
Shigella spp. | 1 | 0.2 | 4.3 | 0.1–24.1 | |
Yersinia spp. | 1 | 0.4 | 2.4 | 0.06–13.4 | |
Other necrotizing vasculopathies (Goodpasture syndrome, TTP, Wegener granulomatosis, giant cell arteritis) | Campylobacter spp. | 10 | 3.3 | 3.1 | 1.5–5.6 |
EHEC | 0 | <0.05 | 32.8 | 0.8–183.0 | |
Salmonella spp. | 1 | 2.1 | 0.5 | 0.01–2.7 | |
Systemic lupus erythematosus | Campylobacter spp. | 5 | 3.4 | 1.5 | 0.5–3.4 |
Salmonella spp. | 2 | 2.1 | 1.0 | 0.1–3.5 | |
Systemic sclerosis | Campylobacter spp. | 2 | 1.7 | 1.2 | 0.2–4.4 |
Salmonella spp. | 3 | 1.1 | 2.8 | 0.6–8.1 | |
Other systemic involvement of connective tissue (Sjögren syndrome, mixed connective tissue disease, polymyalgia rheumatica) | Campylobacter spp. | 12 | 5 | 2.4 | 1.2–4.2 |
Salmonella spp. | 4 | 3.1 | 1.3 | 0.4–3.3 | |
Shigella spp. | 1 | 0.2 | 4.2 | 0.1–23.3 | |
Ankylosing spondylitis | Campylobacter spp. | 2 | 1.1 | 1.8 | 0.2–6.4 |
Salmonella spp. | 1 | 0.7 | 1.5 | 0.04–8.1 |
*Obs, observed number of cases; Exp, expected number of cases; SIR, standardized incidence ratio; CI, confidence interval; EHEC, enterohemorrhagic Escherichia coli.; TTP, thrombotic thrombocytopenic purpura.